Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control Study

BACKGROUND: We previously reported that biofilms and innate immunity contribute to the pathogenesis of Kawasaki disease. Therefore, we aimed to assess the efficacy of clarithromycin, an antibiofilm agent, in patients with Kawasaki disease. METHODS AND RESULTS: We conducted an open‐label, multicenter...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Am Heart Assoc
Hauptverfasser: Nanishi, Etsuro, Nishio, Hisanori, Takada, Hidetoshi, Yamamura, Kenichiro, Fukazawa, Mitsuharu, Furuno, Kenji, Mizuno, Yumi, Saigo, Kenjiro, Kadoya, Ryo, Ohbuchi, Noriko, Onoe, Yasuhiro, Yamashita, Hironori, Nakayama, Hideki, Hara, Takuya, Ohno, Takuro, Takahashi, Yasuhiko, Hatae, Ken, Harada, Tatsuo, Shimose, Takayuki, Kishimoto, Junji, Ohga, Shouichi, Hara, Toshiro
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2017
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5586277/
https://ncbi.nlm.nih.gov/pubmed/28684643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.116.005370
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge